Roivant Sciences Ltd.
—- Market cap
- —
- Debt
- +$412.94M
- Cash
- −$4.29B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ROIV stock price vs INTU: inconclusive — current versus $0.06 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at INTU's multiple
Implied fair value · at ROIV's multiple
Needs ROIV P/S.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ROIV FY 2026 (ended Mar 31, 2026) · INTU FY 2025 (ended Jul 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 94% equity / 6% debt · EV / Revenue 5.00x · EV / EBITDA 16.30x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
INTUIT INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.09x
0.30x
Net debt / EBITDA
Leverage against operating earnings
24.52x
0.54x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$2.88B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
AUTOMATIC DATA PROCESSING INC
ROIV vs ADP
PAYCHEX INC
ROIV vs PAYX
H&R BLOCK INC
ROIV vs HRB
Oracle Corporation
ROIV vs ORCL
$412.94M
$5.97B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ROIV can rapidly and durably improve revenue growth, margins, and cash generation, then avoid using INTU as a valuation anchor because the current data imply extreme overvaluation relative to INTU; otherwise, the data support a sell or underweight view on ROIV.
ROIV's current price of $35.13 is far above INTU-implied range of $0.05 to $2.94, implying a -99.9% downside versus the INTU-based P/S valuation. The gap is driven by ROIV's extremely high sales and earnings multiples relative to INTU, despite much weaker fundamentals.
Supporting Metrics